Background Deaths in HIV-positive people have decreased since the introduction of highly active antiretroviral therapy (HAART) in 1996. Fewer AIDS-related deaths and an ageing cohort have resulted in an increase in the proportion of HIV patients dying from non-AIDS-related disorders. Here we describe mortality and causes of death in people diagnosed with HIV in the HAART era compared with the general population.
Introduction
Since highly active antiretroviral therapy (HAART) was introduced in the UK in 1996, mortality in HIV-positive people has decreased substantially and modelling suggests that life expectancy of those diagnosed soon after infection and started on treatment is approaching that of the general population. 1, 2 In the UK, the annual number of deaths in the HIV-positive population fell from 1730 in 1995, to 490 in 2012, 3 largely because of a reduction in deaths from AIDS. 2 Fewer AIDS-related deaths and an ageing cohort have resulted in an increase in the proportion of HIV patients dying from non-AIDS-related disorders, such as cardiovascular disease (CVD), cancer, and liver disease. 4, 5 Monitoring causes of death in HIV-positive people enables appropriate targeting of interventions to improve the quality of patient care and reduce avoidable mortality. In England and Wales, all deaths are reported to the national mortality register. These reports are linked every year to the comprehensive national cohort of people diagnosed with HIV and accessing care under the National Health Service (NHS). By the end of 2012, 77 610 people diagnosed with HIV were under active follow up, providing a unique opportunity to track all-cause mortality in the HAART era. 3 The Coding Causes of Death in HIV (CoDe) protocol standardises the classifi cation of causes of death in HIV-positive people using death certifi cate data and clinical markers and is used widely in Europe and the USA. [4] [5] [6] In this study, a modifi ed CoDe protocol was applied to describe causes of death among people diagnosed with HIV, changes in mortality in the era of HAART, and compare mortality with the general population.
Methods

Data sources
Public Health England (PHE) collects cohort data for all people diagnosed with HIV in the UK as part of the national HIV surveillance programme. Cohort inclusion begins at diagnosis with follow-up clinical information collected every year from all 220 NHS HIV outpatient clinics nationwide.
Patient data are annually linked to the Offi ce for National Statistics (ONS) death data, using pseudoanonymised identifi ers. ONS provides PHE with all-cause death data by death-year for people who died before the
Research in context
Evidence before this study To assess the research comparing mortality of HIV-positive people to the general population, we searched Ovid MEDLINE up to Feb 24, 2016 , including in-process and other non-indexed citations published in all languages. Search terms included: (MeSH headings: "HIV/" or "HIV-2/" or "HIV-1/" or "HIV Infections/" or "Acquired Immunodefi ciency Syndrome/") OR (keywords in title/abstract: "HIV" or "HIV infect*" or "HIV patient" or "HIV 1" or "HIV 2" or "HIV 1 infect*" or "HIV 2 infect*" or "human immunodefi ciency virus" or "acquired immune defi ciency syndrome" or "acquired immunodefi ciency syndrome" or "AIDS") AND (keywords in title/abstract: "standardised mortality" or "standardized mortality").
There were 152 search results of which 20 were eligible for further review, from western countries and presenting standardised mortality ratios (SMRs). Estimates varied widely between studies and countries and the ability to compare was dependent upon the SMR stratifi cations (all-cause vs breakdown by sex, cause of death, clinical markers, and so on). Of the 20 included studies, 13 described mortality among patients enrolled in HIV care and undergoing routine follow-up, with six focusing solely on those patients receiving antiretroviral therapy (ART) ( [SMART] ). Where all-cause SMRs were presented for those on treatment, mortality of HIV-positive patients was 1·2-4·2 times that of the general population, excluding the one study from the ANRS cohort which estimated mortality to be as high as 7·0 (95% CI 6·2-7·8) among patients starting treatment with protease inhibitors.
Four studies described mortality and calculated SMRs using case-based surveillance matched to mortality data from a vital statistics register or death reports. One small study (n=210 deaths), in Spain, estimated all-cause mortality of 20-59 year olds diagnosed with HIV between 1999 and 2006 to be 14 times that of the general population, while a slightly larger Italian study (n=1211) found the all-cause mortality SMR to be 6·0 (SMR 4·5 men and 9·4 women). The two remaining surveillance studies (in San Francisco, CA, USA) estimated mortality in men diagnosed with HIV from 1994-1998 (n=5234) and 1996-2011 (n=5538) compared with the general population. Rather than all-cause mortality, results were stratifi ed by cause of death. The more recent of the two studies showed an increased risk of death from non-AIDS cancers, heart, and liver disease in people with HIV compared with the general male population.
Added value of this study
To the best of our knowledge, this is the largest study to compare mortality of HIV-positive people diagnosed in the era of eff ective HAART with that of the general population, and the only study up to now to present standardised mortality ratios by both cause of death and sex. Our fi ndings are based on a comprehensive national cohort of all people diagnosed with HIV from the date of fi rst diagnosis, including people that present late and those never linked to HIV care, usually missed in clinical HIV cohorts. The eff ect of this inclusion on mortality is profound and can be seen in the high burden of AIDS deaths in our study population. Even when AIDS deaths were excluded, mortality in our cohort remained double that of the general population. In the fi rst year post-diagnosis, mortality was 24 times higher, dropping to 2·8 that of the general population in subsequent years. Though survival was found to improve over time for the cohort, mortality compared with the general population was still elevated among those diagnosed in recent years.
Implications of all the available evidence
Data from treatment and care cohorts have provided evidence of the benefi t of HAART in reducing mortality among the HIV-positive population. However, our data highlight the importance of prompt diagnosis and linkage to care in reducing mortality in the coming years, in addition to optimum prevention and management of comorbidities.
age of 65 years and AIDS-only death data for those aged 65 years and older. Linkage is otherwise unreliable in those who died aged 65 years or older because of the high number of deaths in this age group. However, PHE also receives death reports, irrespective of age at death, from HIV clinicians through routine surveillance and annual death auditing. When cause of death was available from multiple sources, ONS data were used.
Death data for the general population in England and Wales by sex, age, and primary cause according to the 10th revision of the International Statistical Classifi cation of Diseases and Related Health Problems (ICD-10) by death year, were obtained from the ONS website, along with data for population size by sex and age. 
Population
People diagnosed with HIV between 1997 and 2012 in England and Wales, aged 15 years and older at diagnosis, were followed up to the end of 2012 (data extracted January, 2014). Analyses were restricted to people diagnosed in England and Wales due to the availability of comparable ONS data on causes of death in the general population in Scotland and Northern Ireland.
Defi nitions
Late diagnosis was defi ned as a CD4 count of less than 350 cells per mm³ within 3 months of diagnosis. A patient was considered linked to care if they had at least one attendance in an HIV outpatient clinic after diagnosis. 8 
Categorisation of cause of death
Two independent reviewers (one epidemiologist [either SC or MK] and one public health physician [either AK or ME]) categorised deaths; senior HIV medical epidemiologists (VD, AKS, and AS) adjudicated discrepancies, as per the CoDe protocol. 6 CoDe categories were adapted to account for the way HIV surveillance data are collected in the UK; clinical markers are reported to PHE at last HIV outpatient clinic attendance in a given year and might not refl ect information at time of death. 6, 9 Deaths were categorised on the basis of reported cause. Data for clinical markers were considered where information was incomplete to distinguish AIDS and non-AIDS infections (appendix p 1). 
Descriptive analyses
Statistical analysis
For Kaplan-Meier survival curves and mortality rate estimation, we used HIV diagnosis date as time of entry, and follow up was censored on either the death date or the date last seen for HIV care. For cause-specifi c analyses, data were also censored at death date from any other or unknown cause. People who neither died nor were seen for HIV care after diagnosis were censored at entry (n=3820) and excluded from time-to-event analysis. However, these individuals were included in all Sex was reported for 100% of individuals (n=88 993); age at diagnosis: 100% (n=88 994); year of diagnosis: 100% (n=88 994); country of birth: 73% (n=64 826); infection route: 97% (n=86 009); CD4 count at diagnosis: 69% (n=60 920). *Mortality rate per 10 000 person-years. descriptive analysis to understand the population diagnosed with HIV in the HAART era. The appendix provides more information about those who were not followed up (appendix p 3). We used the log-rank test to compare survival between groups. We used Cox regression to determine independent predictors of all-cause mortality, adjusting for sex, infection route, age at diagnosis, region of birth, year of diagnosis, late diagnosis, and history of HAART, because of missing data for treatment start date.
To compare the cohort mortality to the general population, we calculated standardised mortality ratios (SMRs) using 5-year age bands, stratifying by sex, cause of death, and time since diagnosis; 95% confi dence intervals (CIs) were calculated using Poisson distribution. We applied the distribution of cause of death in the population for 1999 to the general population for the years 1997 and 1998 because ONS data for these 2 years were unavailable. All analyses were done with Stata (version 13.0).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The fi rst fi ve authors of this paper had full access to the data (SC, AK, SD, MK, and ME); the corresponding author (SC) had fi nal responsibility to submit for publication.
Results
Between 1997 and 2012, 88 994 adults were diagnosed with HIV in England and Wales, contributing 448 839 person-years of follow up (table 1; Women were diagnosed at an earlier age (median age 32 years in women vs 36 years in men) and a higher proportion were diagnosed late compared with men (61% women vs 51% men). From 1997 to 2012, HIV diagnoses rose continuously in men who have sex with men (MSM), people born in the UK, and all older age groups (appendix p 2). By contrast, diagnoses in heterosexuals, especially women, and those born in sub-Saharan Africa decreased from 2003 onwards. Late diagnosis decreased from 61% in 1997 to 46% in 2012 (appendix p 2).
By the end of 2012, 5302 (6%) of 88 994 people in the cohort had died, representing an all-cause mortality rate of 118 per 10 000 person-years (95% CI 115-121; table 2). Survival probability of the whole cohort at 1, 5, 10, and 15 years from diagnosis was 96% (95% CI 96·1-96·4), 94% (93·7-94·1), 91% (91·0-91·6), and 88% (87·7-88·8), respectively. The fi gure shows Kaplan-Meier survival 
Time Sex was reported for 100% of individuals (n=88 993); age at diagnosis: 100% (n=88 994); year of diagnosis: 100% (n=88 994); country of birth: 73% (n=64 826); infection route: 97% (n=86 009); CD4 count at diagnosis: 69% (n=60 920). *Mortality rate per 10 000 person-years. estimates of changes in survival over time by diagnosis year group, and the appendix provides further breakdowns by sex, age at diagnosis, region of birth, probable exposure, and CD4 at diagnosis (pp 6-15). Overall, cohort survival improved signifi cantly across diagnosis year groups (log-rank p<0·0001).
The rate of all-cause mortality was higher in men (130 per 10 000 person-years, 95% CI 126-134) than women (96·8, 92·2-102; table 2). Mortality increased with age at diagnosis and was higher in UK-born people than in those born elsewhere. People who inject drugs had the highest mortality rate (331 per 10 000 person-years, 95% CI 297-369); mortality was lowest in heterosexual women (81·3, 79·6-85·9). Mortality in people with low CD4 counts at diagnosis was high (tables 2 and 3). People linked to HIV care after diagnosis had an all-cause mortality rate of 90·6 per 10 000 person-years (95% CI 87·9-93·4).
In multivariable analysis, a high risk of death was associated with being diagnosed late (table 4). People exposed to HIV through injecting drug use, heterosexual contact, and other routes had a higher risk of death than men infected through sex between men. Risk increased with age at diagnosis. The highest risk of death was associated with never being on HAART. Being a woman and being born outside the UK were associated with a lower risk of death ( Tables 2 and 3 show cause-specifi c mortality rates by key descriptive variables. Mortality rates were higher for men and those born in the UK across all causes. People with lower CD4 counts and diagnosed at an older age had consistently higher mortality. People who inject drugs had higher mortality rates from liver disease, accident, and substance misuse compared to those infected through other routes. Mortality due to AIDS-defi ning illnesses was the highest across all demographic characteristics (table 2) .
Patients who died from AIDS had the lowest median CD4 count at diagnosis (65 cells/mm 3 (table 5) . For those who died from AIDS who did attend for outpatient care, treatment uptake was low at 57%. Almost three-quarters of AIDS deaths occurred within 1 year of diagnosis compared with 37% of non-AIDS deaths (table 5) . During the study period, mortality of the HIV cohort was six times higher than the general population, matched by age and sex (SMR 5·7, 95% CI 5·5-5·8), and remained raised after excluding AIDS deaths (2·2, 2·1-2·3; table 6). Cohort mortality was especially high for non-AIDS infections (SMR 10·8, 95% CI 9·8-12·0) followed by liver disease (3·7, 3·3-4·2) and substance misuse (2·6, 2·1-3·1). All-cause mortality in HIV-positive men was 4·9 times higher and HIV-positive women 8·8 times higher than their general population counterparts. SMRs were highest for non-AIDS infections (SMR in men 8·8, 95% CI 7·7-10·1; in women 18·3, 15·3-21·7) and liver disease (in men 3·6, 3·1-4·1; in women 4·1, 3·0-5·4).
Cohort mortality across all causes was much higher in the year after HIV diagnosis than later (all-cause: SMR 24·3, 95% CI 23·4-25·2 vs 2·8, 2·7-2·9) and for the most part remained higher than the general population for both time periods (tables 6-8). Only mortality due to non-AIDS cancers, CVD and stroke, and accidental death dropped to become similar to those in the general population after the fi rst year of diagnosis. Mortality due to non-AIDS infections in women in the year following HIV diagnosis was 64·0 times higher than the general population (95% CI 49·3-81·7) and remained 10·7 times higher (8·2-13·6) in subsequent years (table 6). Mortality in women from accident, suicide, and substance misuse was similar to that of the general population in the fi rst year after diagnosis and onwards (tables 6-8).
The appendix (pp [16] [17] [18] shows changes in cohort mortality in the year after diagnosis compared with the general population by diagnosis year. Even in more recent years, mortality in the fi rst year was raised compared with the general population across all causes.
Discussion
While mortality in the subgroup of people diagnosed with HIV who are promptly linked to care and successfully Data are n (%) or median (IQR). *At least one attendance in an HIV outpatient clinic following diagnosis. 8 Table 5 : Clinical characteristics and timing of death in patients who died by cause of death treated is nearing that of the general population, 10 our fi ndings show that overall, the HIV-positive population has a six times higher risk of death than the general population. Delays in testing, linkage to care, and treatment are major factors that contribute to this increased mortality.
Our fi ndings are consistent with the scientifi c literature showing that mortality in HIV-positive people has declined in the past 20 years. 2, 5 The improvement in survival recorded in this study is the result of improvements in treatment and earlier initiation, 11 as well as a shift in HIV epidemiology. Changes in migration patterns in the UK in the past decade have led to both a decrease in the number of diagnoses in people born in sub-Saharan Africa and the proportion of people born in the sub-Saharan Africa diagnosed late. 12 There has also been a decrease in late presentation in MSM associated with increased testing uptake and frequency. 3, 12 Unlike most observational cohort studies that typically enrol HIV patients in clinical care or on treatment, [4] [5] [6] 13 this study includes individuals from the point of diagnosis, capturing those who present late or never link to HIV outpatient care. The eff ect of this inclusion can be seen in the high number of deaths in the cohort compared with those expected in the general population, even in recent years. Overall, all-cause mortality was 5·7 times higher than that of the general population of England and Wales, matched by age and sex. This fi gure is much higher than mortality reported in international treatment cohorts which estimate mortality to be between 1·2 and 4·2 times higher than the general population over similar time periods. 10, 14, 15 However, it is consistent with another smaller surveillance study in Italy including HIV patients from diagnosis (overall SMR 6·0, 4·5 in men, 9·4 in women). 16 Our fi ndings also show that men had a higher overall death rate than women but paradoxically women had a higher SMR than men. This fi nding is most likely because of higher deaths rates in younger men in the general population. When stratifi ed by time since diagnosis, all-cause mortality of the cohort in the fi rst year after diagnosis was as high as 24 times that of the general population, compared with only 2·8 times from 1 year after diagnosis onwards. Mortality remained raised across all causes, even among those diagnosed in recent years, probably because of continuing high rates of late presentation, also reported across other European countries, 17 which substantially eff ect survival early on. In the UK, people diagnosed late have a ten times higher risk of death within 1 year of diagnosis than those diagnosed promptly 18 and 3·5 times the risk of death overall. Our results also suggest that late diagnosis remains a major predictor of death from all causes.
AIDS continues to account for the highest proportion of deaths despite the availability of free HIV treatment and care in the UK through the NHS. This is much higher than previously published estimates of AIDS deaths in people accessing care (58% vs 33-43%). 2, 19, 20 In this cohort, the vast majority (87·1%) of people who died from AIDS were diagnosed late and a high proportion never linked to HIV outpatient care (28·5%). National HIV testing guidelines recommend various strategies to increase testing thereby reducing late diagnosis, including testing of HIV indicator-conditions and expanded testing outside of specialist sexually transmitted infection clinics in areas with high diagnosed prevalence. 21 However, a 2013 audit of these guidelines found adherence to be poor outside of sexual health and antenatal clinics. 22 It is crucial that HIV testing rates be increased; these analyses show a substantial number of deaths could have been prevented through earlier detection and that clear referral pathways are needed to ensure that once Non-AIDS disorders accounted for 42% of deaths overall, and after AIDS deaths were excluded, non-AIDS mortality in our cohort was double that of the general population. However, the risk of non-AIDS mortality was signifi cantly lower for people who had been diagnosed with HIV for more than 1 year. Mortality due to cancer and CVD in this subgroup was equal to that of the general population, though still elevated overall. This is consistent with evidence that though the risk of non-AIDS mortality is lower for treated patients compared with untreated patients, the incidence of cancer, liver disease, and CVD remain higher in the HIV-positive population than in the general population. 24, 25 The incidence of CVD and non-AIDS cancers might be higher in HIV-positive people because of chronic low-level infl ammation, which can promote carcinogenesis. 26 Additionally, lifestyle risk factors, such as obesity and smoking, are prevalent in this population. 27, 28 Long-term HIV treatment might also be associated with increased CVD-related risk and serious adverse events, though our data show a diff erence in CVD mortality between men and women and published evidence is inconsistent. 29 Previous studies have reported HIV-positive women are at signifi cantly higher risk of severe bacterial non-AIDS infections 30 and hospital admission for non-AIDS infections compared with men. 31 This is the fi rst study to report higher mortality due to non-AIDS infections among HIV-positive women in the era of eff ective treatment. These fi ndings warrant further investigation.
The higher mortality due to liver disease in HIV-positive people compared with the general population, irrespective of the time from HIV diagnosis, is most likely multifactorial, including the use of hepatotoxic antiretroviral drugs compounded by co-infections and lifestyle factors, such as obesity and alcohol misuse. 24 High levels of substance misuse and depression among MSM diagnosed with HIV have been reported, 32 and might account for the high cohort mortality due to suicide and overdose seen among men. In this study, suicide was fi ve times higher than the general population in the year after diagnosis. This could even be an underestimate, as suicide death classifi cation relied on death certifi cate data on intent.
Our fi ndings suggest that to further reduce avoidable mortality, there must be optimal detection of comorbidities among people living with HIV, particularly in the fi rst year after diagnosis, such as routine screening for CVD risk, depression, drug and alcohol misuse, cognitive diffi culties, and blood-borne viruses, as suggested by the British HIV Association. 23 Prevention measures should be strengthened, including smoking cessation, nutritional support, and drug and alcohol counselling. Furthermore, given the low median age of death and CD4 count at diagnosis seen among patients dying from non-AIDS, reducing late diagnosis could also reduce premature deaths from these causes. Future work will examine predictors of non-AIDS mortality.
Strengths of this study include the large size, comprehensive national coverage of all HIV-positive people followed up from diagnosis, and the use of the internationally validated CoDe protocol in death classifi cation. To our knowledge, this is the largest and most complete report on HIV mortality to date in the UK. However, by design, this study is subject to limitations inherent to all retrospective cohort studies, particularly those constructed from clinical databases. Analysis was restricted to available data, meaning that some factors of In addition to missing data, diff erential loss to follow up might have also led to bias, particularly through under-ascertainment of deaths occurring abroad. At least half of this cohort were born abroad, and an analysis of the 3503 individuals lost to follow up for more than 5 years before 2012 showed that the majority were sub-Saharan Africa born, heterosexual women, likely to have emigrated out of the country. 33 Emigration data are not collected as part of national HIV surveillance and it is not possible to link to a national register. This was taken into consideration in the decision to right censor on the date last seen for care in the UK, which limited the analysis to confi rmed follow-up time and excluded people with no follow up after diagnosis by default. Though this method of censorship might have resulted in higher mortality estimates, individuals are unlikely to remain well without accessing HAART through HIV specialist services for a long period of time, and given the high proportion of those lost to follow-up who were born abroad, we feel it is more likely that these people have either left the UK or record linkage was not possible due to coding errors in patient identifi ers or name changes, resulting in duplicate patients.
Surveillance and death data might be subject to reporting delays and poor linking due to incomplete identifi ers. Multiple reporting sources and triangulation of data reduce these biases. Over 95% of HIV-positive patients can be linked across clinics and calendar years in the UK. 3 Finally, whilst clinicians report all-cause mortality among patients regardless of age, reports received from ONS include all AIDS deaths and deaths from any cause in those aged <65 years. The number of deaths in those aged ≥65 might therefore be under-reported and the mortality rates in this group should be interpreted with caution. The eff ect of this reporting bias might be mitigated by the fact this group comprises only 3·0% of the cohort, 0·70% of the total cohort person-years, and that deaths might be captured through audits and clinician reports.
Despite the availability of free antiretroviral treatment in the UK, mortality in HIV-positive people continues to be higher than that of the general population, with AIDS being the leading cause of death. These fi ndings highlight the importance of prompt diagnosis and linkage to care as major public health interventions to reduce premature mortality. HIV testing should be further expanded outside traditional settings to reach vulnerable populations and patients supported across the HIV care pathway. As people live longer with HIV, prevention and optimal management of comorbidities might further reduce mortality. Robust surveillance data for deaths and cause of death are crucial, as mortality is a key marker of the eff ectiveness of a country's HIV strategy and should be a standardised indicator in international HIV reporting. 
